menu
    • menu
    [{"orgOrder":0,"company":"Europharma","sponsor":"Europharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ASC-J9","moa":"Androgen receptor (AR)","graph1":"Dermatology","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Europharma \/ Europharma","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ Europharma"},{"orgOrder":0,"company":"Europharma","sponsor":"Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Red Ginseng","moa":"Aryl hydrocarbon receptor; Interleukin-6; Prostaglandin G\/H synthase 2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia"},{"orgOrder":0,"company":"Europharma","sponsor":"Europharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"EGYPT","productType":"Steroid","year":"2019","type":"Inapplicable","leadProduct":"Fluticasone Furoate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Europharma","highestDevelopmentStatusID":"11","companyTruncated":"Europharma \/ Europharma"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"2ccPA","moa":"Lysophosphatidic acid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"2ccPA","moa":"Lysophosphatidic acid receptor","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Europharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"NC-6004","moa":"polymers; antineoplastics (platinum derivatives); PEGylated compounds","graph1":"Oncology","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Europharma","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ Europharma"},{"orgOrder":0,"company":"Europharma","sponsor":"NanoCarrier Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NC-6004","moa":"polymers; antineoplastics (platinum derivatives); PEGylated compounds","graph1":"Oncology","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Europharma \/ NanoCarrier Ltd","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ NanoCarrier Ltd"},{"orgOrder":0,"company":"Europharma","sponsor":"NanoCarrier Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"NC-6004","moa":"polymers; antineoplastics (platinum derivatives); PEGylated compounds","graph1":"Oncology","graph2":"Phase III","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ NanoCarrier Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Europharma \/ NanoCarrier Ltd"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mitiglinide Calcium","moa":"Sulfonylurea receptor 1, Kir6.2","graph1":"Endocrinology","graph2":"Phase IV","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Center of Drug and Medical Technologies Expertise, Armenia | Cardiomed LLC | Institute of Fine Organic Chemistry of the National Academy of Science, Armenia | Phytomed AB","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Berberine","moa":"Telomerase reverse transcriptase (TERT)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Center of Drug and Medical Technologies Expertise, Armenia | Cardiomed LLC | Institute of Fine Organic Chemistry of the National Academy of Science, Armenia | Phytomed AB","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ Center of Drug and Medical Technologies Expertise, Armenia | Cardiomed LLC | Institute of Fine Organic Chemistry of the National Academy of Science, Armenia | Phytomed AB"},{"orgOrder":0,"company":"Europharma","sponsor":"Orient Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"1PC002","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Europharma \/ Europharma","highestDevelopmentStatusID":"10","companyTruncated":"Europharma \/ Europharma"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Andrographolide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"Curamed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Simon Khechinashvili University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Echinacea Angustifolia","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Europharma \/ Simon Khechinashvili University","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ Simon Khechinashvili University"},{"orgOrder":0,"company":"Europharma","sponsor":"I.Zhordania Institute of Reproductology","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"EP-40","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ I.Zhordania Institute of Reproductology","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ I.Zhordania Institute of Reproductology"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HRG80 Hydroponic Red Ginseng","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Botalys","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"HRG80 Panax ginseng","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Botalys","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ Botalys"},{"orgOrder":0,"company":"Europharma","sponsor":"Medinox","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"NOX-100","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Europharma","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ Europharma"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Sarcojoint","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Powder","sponsorNew":"Europharma \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Europharma \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"John E. Eaton","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2016","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I\/ Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Europharma \/ John E. Eaton","highestDevelopmentStatusID":"7","companyTruncated":"Europharma \/ John E. Eaton"}]

    Find Clinical Drug Pipeline Developments & Deals by Europharma

    Menu

    Europharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sarcojoint

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung ...

                            Details : Sarcojoint is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Sarcopenia.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            July 03, 2023

                            Lead Product(s) : Sarcojoint

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2ccPA

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

                            Details : 2ccPA is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2023

                            Lead Product(s) : 2ccPA

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Red Ginseng

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Gamma-cyclodextrin on the Bioavailability of Ginsenosides

                            Details : Red Ginseng is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 21, 2021

                            Lead Product(s) : Red Ginseng

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Phytomed AB | Center of Drug and Medical Technologies Expertise, Armenia | CARDIOMED Family Health Center, LLC of the Ministry of Health of Armenia | Institute of Fine Organic Chemistry of the National Academy of Science Yerevan, Armenia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Berberine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Center of Drug and Medical Technologies Expertise, Armenia | Cardiomed LLC | Institute of Fine Organic Chemistry of the National Academy of Science, Armenia | Phytomed AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Gamma-cyclodextrin on the Bioavailability of Berberine

                            Details : Berberine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            June 09, 2021

                            Lead Product(s) : Berberine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Center of Drug and Medical Technologies Expertise, Armenia | Cardiomed LLC | Institute of Fine Organic Chemistry of the National Academy of Science, Armenia | Phytomed AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mitiglinide Calcium

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)

                            Details : Mitiglinide is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 16, 2020

                            Lead Product(s) : Mitiglinide Calcium

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2ccPA

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            2ccPA Study in Patients With Symptomatic Knee Osteoarthritis

                            Details : 2ccPA is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : 2ccPA

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate the Effect of Dietary Supplement on Muscle Mass and Physical Performance for Over 50 Years Old People

                            Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Muscular Atrophy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 18, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluticasone Furoate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

                            Details : Fluticasone Furoate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            December 04, 2019

                            Lead Product(s) : Fluticasone Furoate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Recipient : Genuine Research Center, Egypt

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HRG80 Hydroponic Red Ginseng

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Korean Red Ginseng Extract on Electrical Brain Activity in Elderly Subjects

                            Details : HRG80 Hydroponic Red Ginseng is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 18, 2019

                            Lead Product(s) : HRG80 Hydroponic Red Ginseng

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Europharma

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HRG80 Panax ginseng

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Botalys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ginseng HRG80 in Stress and Fatigue

                            Details : HRG80 Panax ginseng is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stress Disorders, Traumatic.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 13, 2019

                            Lead Product(s) : HRG80 Panax ginseng

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Botalys

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth